Trial · NCT00524342

IL-11 in Women With Von Willebrand Disease and Refractory Menorrhagia

NCT00524342, Phase 2, Completed, Margaret Ragni; results first posted 2014-11-07

3 sourcestrials-2026-11-12-0.5.0

Cite this record

ConductScience Library. IL-11 in Women With Von Willebrand Disease and Refractory Menorrhagia. Trials, record NCT00524342. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT00524342

On this page

Trial

As registered on ClinicalTrials.gov, in the graph's capture of the registry.

Title: IL-11 in Women With Von Willebrand Disease and Refractory Menorrhagia
NCT number: NCT00524342
Status: Completed
Phases: Phase 2
Enrollment: 7 participants, actual
Lead sponsor: Margaret Ragni
Conditions: Von Willebrand Disease
Interventions: Oprelvekin, Interleukin 11, IL-11
First posted: 2007-09-03
Last updated: 2018-01-31
Results first posted: 2014-11-07

Source ClinicalTrials.gov

Registered outcomes3

Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.

List	Outcome	Time frame	Description
Primary	>50% Reduction in PBAC (Pictorial Blood Assessment Chart) at 6 Months	6 months	Subjective estimate of blood loss was measured by using a Pictorial blood assessment chart (PBAC) . The PBAC measures scores on a scale where 0 to 100 is normal and greater than 100-200 are abnormal.
Secondary	No. of Subjects With Detectable VWF mRNA (Von Willebrand Factor Messenger RNA).	The time frame is up to 7 months per subject.	No. of subjects with detectable VWFmRNA, a measure of IL-11 (interleukin-11) function, specifically increasing VWF synthesis.
Secondary	No. of Subjects With IL-11 Associated Adverse Events.	The time frame is up to 7 months per subject.	The number of subjects with IL-11 associated adverse events.

Source ClinicalTrials.gov

Outcomes3

Each outcome the trial posted results for, in ClinicalTrials.gov's words.

Type	Outcome	Time frame	Units	Measured as
PRIMARY	>50% Reduction in PBAC (Pictorial Blood Assessment Chart) at 6 Months	6 months	percentage of participants	NUMBER
SECONDARY	No. of Subjects With Detectable VWF mRNA (Von Willebrand Factor Messenger RNA).	The time frame is up to 7 months per subject.	participants	NUMBER
SECONDARY	No. of Subjects With IL-11 Associated Adverse Events.	The time frame is up to 7 months per subject.	participants	NUMBER

Source ClinicalTrials.gov

Results by group5

Each measurement the trial posted, group by group, in the words and numbers it posted.

Outcome	Group	Category	Value	Units
>50% Reduction in PBAC (Pictorial Blood Assessment Chart) at 6 Months	IL-11		71	percentage of participants
No. of Subjects With Detectable VWF mRNA (Von Willebrand Factor Messenger RNA).	IL-11		7	participants
No. of Subjects With IL-11 Associated Adverse Events.	IL-11	fluid retention	6	participants
No. of Subjects With IL-11 Associated Adverse Events.	IL-11	injection site bruising	6	participants
No. of Subjects With IL-11 Associated Adverse Events.	IL-11	flushing	3	participants

Source ClinicalTrials.gov

Participant flow3

How many started, completed or left each group, period by period.

Period	Milestone	Group	Participants
Overall Study	STARTED	IL-11	7
Overall Study	COMPLETED	IL-11	7
Overall Study	NOT COMPLETED	IL-11	0

Source ClinicalTrials.gov

Adverse events7

Each adverse event the trial posted, group by group: the participants affected out of those at risk.

Type	Event	Organ system	Group	Affected	At risk
other	conjunctival erythema	Skin and subcutaneous tissue disorders	IL-11	7	7
other	fluid retention	General disorders	IL-11	6	7
other	injection site bruising	General disorders	IL-11	6	7
other	flushing	General disorders	IL-11	3	7
other	thrombocytosis	Blood and lymphatic system disorders	IL-11	1	7
other	hypokalemia	Renal and urinary disorders	IL-11	1	7
other	diastolic hypertension	Renal and urinary disorders	IL-11	1	7

Source ClinicalTrials.gov

Adverse event totals3

The totals the trial posted for each group.

Total	Group	Affected	At risk
Total, all-cause mortality	IL-11
Total, other adverse events	IL-11	7	7
Total, serious adverse events	IL-11	0	7

Source ClinicalTrials.gov

Papers2

The papers the trial lists on ClinicalTrials.gov.

PMID	Listed as	Source
18680527	BACKGROUND	PubMed
21833452	RESULT	PubMed

Grants0

The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.

None in this release.

Trial comparisons0

Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.

None in this release.

Tests0

The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.

None in this release.

Data dates

The day each source was copied for this release.

ClinicalTrials.gov: 2026-11-12; ClinicalTrials.gov
Results, from AACT: 2026-03-23; AACT
NIH grant links: 2026-11-13; NIH RePORTER

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this trial from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/trials/v1/NCT00524342

GET https://conductscience.org/api/trials/v1/NCT00524342/registered

API reference For AI assistants